Rubitecan liposomal

Drug Profile

Rubitecan liposomal

Alternative Names: 9-Nitrocamptothecin liposomal; Inhaled rubitecan; Rubitecan - Clayton Foundation for Research/SuperGen; Rubitecan liposomal aerosol

Latest Information Update: 12 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clayton Foundation for Research
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer metastases; Lung cancer

Most Recent Events

  • 12 Apr 2007 Discontinued - Phase-I for Lung cancer in USA (Inhalation)
  • 12 Apr 2007 Discontinued - Phase-II for Cancer metastases in USA (Inhalation)
  • 27 Nov 2003 Phase-II clinical trials in Cancer metastases in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top